Abstract 3541
Background
Cancer follow-up care continues to evolve to incorporate complex programs of supportive care to address long-term disease consequences. However, care may be prescriptive and fragmented, contributing to uncertainty among cancer survivors. As major stakeholders in follow-up care for cancer survivors, nurses are ideally positioned to ensure supportive care is person-centred and responsive to patients’ needs. We recently conducted a study to summarize the evidence related to cancer survivors’ preferences for supportive care and examine the ways in which these preferences are embedded in current guidelines and policies informing cancer survivorship care. This presentation discusses specific implications of these findings for oncology nursing.
Methods
Phase 1 of the study comprises an integrative review of the empirical literature regarding cancer survivors’ preferences for supportive care, with literature sourced from bibilographic databases and analysed according to principles of thematic analysis. In Phase 2, clinical practice guidelines and policy documents guiding supportive care in cancer survivorship are evaluated using content analysis methods to ascertain alignment with the findings of Phase 1. Finally, we conduct a critical analysis of the results through the lens of oncology nursing practice.
Results
Findings of the integrative review and content analysis of practice and policy guidelines highlight issues related to where and when supportive care is accessed and the types and features of supportive care services. Given that these gaps intersect with nursing practice, they serve as potential targets of knowledge translation activities. Impacts on survivors’ experiences are illustrated with exemplars derived from recent qualitative studies conducted in Canadian and Irish contexts.
Conclusions
As novel programs are developed to meet the needs of the growing population of cancer survivors, a consideration of survivors’ preferences is essential. We offer specific ways in which nursing practice and scholarship can be leveraged to ensure the translation of this knowledge into care, making visible the survivors’ voice in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract